RT Book, Section
A1 Gruenberg, Katherine
A1 Guglielmo, B. Joseph
A2 Papadakis, Maxine A.
A2 McPhee, Stephen J.
A2 Rabow, Michael W.
SR Print(0)
ID 1165970503
T1 Rifamycins
T2 Current Medical Diagnosis and Treatment 2020
YR 2020
FD 2020
PB McGraw-Hill Education
PP New York, NY
SN 9781260455281
LK accessmedicine.mhmedical.com/content.aspx?aid=1165970503
RD 2022/05/26
AB In  addition  to  its  use  as  a  primary  agent  in  the  treatment  of  tuberculosis,  rifampin  is  used  as  an  adjunct  in  the  treatment  of  S  aureus  infections.  When  used  as  monotherapy,  rifampin  is  associated  with  rapid  emergence  of  resistance  in  staphylococci.  However,  when  added  to  other  primary  antistaphylococcal  agents,  rifampin  improves  outcomes  in  the  treatment  of  infected  prosthetic  hardware.  Due  to  its  rapid  bactericidal  activity,  rifampin  was  hypothesized  to  be  an  effective  adjunct  in  the  treatment  of  S  aureus  bacteremia  without  hardware  present.  Yet,  the  addition  of  rifampin  to  either  an  antistaphylococcal  penicillin  or  glycopeptide  for  the  treatment  of  S  aureus  bacteremia  did  not  result  in  fewer  composite  treatment  failures,  recurrences,  or  deaths.  It  is  possible  that  adjunctive  rifampin  decreases  the  rate  of  S  aureus  bacteremia  recurrence,  but  this  does  not  appear  to  impact  12-week  survival.  Rifampin  is  also  effective  for  the  treatment  of  latent  tuberculosis  infection.